Clinical Trial: Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT07590934) titled 'Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer' on May 11.

Brief Summary: The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.

Study Start Date: May 14

Study Type: INTERVENTIONAL

Condition: Metastatic Prostate Cancer

Intervention: DRUG: AZD2265 (FPI-2265)

AZD2265 (FPI-2265) will be administered as an intravenous (IV) injection.

DRUG: AZD9574

AZD9574 will be administered orally.

DRUG: Docetaxel

Docetaxel will ...